Brain Metastases News and Research

RSS

Next generation KRAS inhibitor divarasib significantly extends lung cancer survival

Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.

26 Oct 2026

New PET imaging approach detects nearly all kidney cancer lesions

A new PET imaging approach detected 97.9% of lesions in clear cell renal cell carcinoma (ccRCC), potentially giving clinicians a more complete picture of the location and extent of a patient's disease, according to research presented today at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM'26).

20 Oct 2026

Fractionated radiation reduces brain cancer recurrence and boosts survival

Mayo Clinic researchers led a multicenter study that found dividing radiation into several treatments, known as fractionated stereotactic radiosurgery, reduced the risk of cancer returning after surgery for brain metastases and was associated with improved survival compared with delivering radiation in a single treatment.

30 Sep 2026

New study uncovers breakthrough window to prevent brain metastasis

Metastasis, the process by which a tumor spreads throughout the body, is associated with the majority of cancer deaths.

29 Sep 2026

Radioactive collagen tiles double survival for brain metastasis patients

A multicenter clinical trial led by researchers at The University of Texas MD Anderson Cancer Center has found that implanting collagen tiles during brain surgery to deliver targeted radiation therapy dramatically improved tumor control, lowered the risk of recurrence and improved overall survival compared to current standard of care for patients with newly diagnosed brain metastases in need of surgical resection.

29 Sep 2026

Focused radiosurgery extends survival for small cell lung cancer patients with brain metastases

Patients with small cell lung cancer (SCLC) that had spread to the brain lived a median of 17 months after focused stereotactic radiosurgery, compared with nine months after an advanced form of whole brain radiation therapy, an unexpected secondary finding from the first randomized phase 3 trial to compare the treatment approaches in this population.

28 Sep 2026

Fractionated radiosurgery extends survival for brain metastasis patients

Delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced the risk of cancer returning at the surgical site compared with delivering the radiation in a single session, according to the results of the Alliance for Clinical Trials in Oncology A071801 presented today at the plenary session of the American Society for Radiation Oncology in Boston.

28 Sep 2026

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

In the SWOG S1827 MAVERICK phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure–free survival (the primary endpoint of the trial), without an apparent difference in overall survival, according to results presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer, in Seoul, Republic of Korea.

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

MRI surveillance alone improves outcomes for patients with small-cell lung cancer

Results from the international phase III SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC).

14 Sep 2026

Laser treatment may extend survival in glioblastoma patients

For patients facing a diagnosis of glioblastoma - one of the most aggressive and devastating forms of brain cancer - the standard path forward has long meant an invasive open-skull surgery and a daunting prognosis.

17 Aug 2026

AI-based methods help uncover hidden roots of tumor metastasis

A cancerous tumor is not a single enemy. It is made up of many different cell populations that can behave in very different ways.

12 Aug 2026

Preoperative radiation boosts immunotherapy response in brain metastases

A new study led by researchers at The University of Texas MD Anderson Cancer Center demonstrated that pre-operative radiation therapy for brain metastases not only targets tumor cells directly but also can activate immune pathways that can make tumors more receptive to immunotherapy.

17 Jun 2026

AI accurately measures mesothelioma tumors for better treatment decisions

Physicians and researchers at the Netherlands Cancer Institute have developed an AI model that outperforms physicians at evaluating treatment response in pleural mesothelioma.

17 Jun 2026

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

PhoreMost Limited, a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers.

From PhoreMost 12 Jun 2026

Brain Metastases News and Research

Next generation KRAS inhibitor divarasib significantly extends lung cancer survival

New PET imaging approach detects nearly all kidney cancer lesions

Fractionated radiation reduces brain cancer recurrence and boosts survival

New study uncovers breakthrough window to prevent brain metastasis

Radioactive collagen tiles double survival for brain metastasis patients

Focused radiosurgery extends survival for small cell lung cancer patients with brain metastases

Fractionated radiosurgery extends survival for brain metastasis patients

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

MRI surveillance alone improves outcomes for patients with small-cell lung cancer

Laser treatment may extend survival in glioblastoma patients

AI-based methods help uncover hidden roots of tumor metastasis

Preoperative radiation boosts immunotherapy response in brain metastases

AI accurately measures mesothelioma tumors for better treatment decisions

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

Implanted collagen tiles double survival for brain metastasis patients

Damon Runyon supports young scientists driving cancer research innovation

Targeted therapy pralsetinib improves outcomes in RET fusion-positive NSCLCs

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News